![9-year follow-up from the RADICALS-HD trial](https://oncodaily.com/pub/uploads/2024/04/6vRu40Fo_400x400-e1717879962499.png)
9-year follow-up from the RADICALS-HD trial
Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University and Research Fellow at shared a post on X about a recent paper by Chris C. Parker et al., commenting:
“A 9-year follow-up from the RADICALS-HD trial showed no significant difference in metastasis-free survival among prostate cancer patients receiving no Androgen Deprivation Therapy (ADT), 6-month ADT, or 24-month ADT after postoperative radiotherapy.
- 492 patients.
- 10 years, 80% (no ADT), 77% (6-month ADT), and 81% (24-month ADT) remained metastasis-free.
Despite the lack of Metastasis Free Survival (MFS) improvement, the trial underscores the need for future research focused on high-risk patients where treatment innovation is most needed.”
Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047) published in ScienceDirect.
Source: Emre Yekedüz/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023